Abstract
Background: An analysis combining data from several clinical trials has raised concern that tamoxifen therapy may increase the risk of a subsequent colorectal malignancy. We conducted a nested case–control study to test this hypothesis.
Methods: A cohort of women diagnosed with breast cancer in 1978–1992 was identified from the western Washington population-based cancer registry. Cases included women who subsequently developed colorectal cancer prior to 1995. Controls were a random sample of the cohort who did not develop a second primary malignancy, matched to cases on age, stage, and year of initial cancer diagnosis. Tamoxifen use was ascertained by medical record abstraction and physician questionnaires.
Results: Thirty-six percent of the 122 cases for whom information could be obtained received tamoxifen versus 38% of 194 controls. Relative to non-users and adjusted for receipt of other therapies, there was no increased risk of colorectal cancer associated with tamoxifen use in general (matched odds ratio [mOR] = 0.9, 95% CI 0.6–1.6), longer durations of use (for ≥37months, mOR = 0.8, 95% CI 0.4–1.9), higher cumulative doses of therapy (for ≥15 g, mOR = 0.8, 95% CI 0.4–1.6), or use that started at least 5 years prior to the end of study follow-up (mOR = 1.1, 95% CI 0.3–3.7).
Conclusions: We found no overall increased risk for colorectal cancer among tamoxifen users.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fisher B, Costantino JP, Wickerman DL, et al. and other National Surgical Adjuvant Breast and Bowel Project Investigators (1998) Tamoxifen for prevention of breast cancer: report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388.
USFDA (1998) Tamoxifen approved for reducing breast cancer incidence. HHS News, U.S. Department of Health and Human Services, P98-34. 29 October. Bethesda, MD: United States Food and Drug Administration (http://www.fda.gov/bbs/topics/NEWS/NEW00662.html).
Rutqvist LE, Johansson H, Signomlklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645–651.
Newcomb PA, Solomon C, White E (1999) Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 53: 271–277.
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, and other NSABP contributors (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the NSABP B-14. J Natl Cancer Inst 86: 527–537.
Cook LS, Weiss NS, Schwartz SM, et al. (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87: 1359–1364.
Breslow NE, Day NE (1980) Statistical Methods in Cancer Research, vol. II: The Analysis of Case—Control Studies. Lyon: International Agency for Research on Cancer.
Potter JD, Slattery ML, Bostick RM, Gapstur SM (1993) Colon cancer: a review of the epidemiology. Epidemiol Rey 15: 499–545.
Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Kitago K, Fazio VW (1996) The effect of tamoxifen on established human colorectal cancer cell lines in vitro. Anticancer Res 16: 3767–3772.
Lointier P, Wildrick DM, Boman BM (1992) Grown effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa. Anticancer Res 12: 1523–1526.
Ziv Y, Fazio VW, Kitago K, Gupta MK, Sawady J, Nishioka K (1997) Effect of tamoxifen on 1,2-dimethylhydrazine-HCl-induced colon carcinogenesis in rats. Anticancer Res 17: 803–807.
Kuruppu D, Christophi C, Bertram JF, O'Brien PE (1998) Tamoxifen inhibits colorectal cancer metastases in the liver: a study in a murine model. J Gastroenterol Hepatol 13: 521–527.
Pongracz K, Pathak DN, Nakamura T, Burlingame AL, Bodell WJ (1995) Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res 55: 3012–3015.
Davies AM, Martin EA, Jones RM, Lim CK, Smith LL, White IN (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 16: 539–545.
White IN, de Matteis F, Davies A, et al. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197–2203.
Han X, Liehr JG (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360–1363.
Shibutani S, Suzuki N, Terashima I, Sugarman SM, Grollman AP, Pearl ML (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol 12: 646–653.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cook, L.S., Weiss, N.S., Pharris-Ciurej, N. et al. Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control 12, 405–410 (2001). https://doi.org/10.1023/A:1011228501440
Issue Date:
DOI: https://doi.org/10.1023/A:1011228501440